The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Fructose-1,6-bisphosphatase opposes renal carcinoma progression
Open accessAbstract
Clear cell renal cell carcinoma (ccRCC), the most common form of kidney cancer, is characterized by elevated glycogen levels and fat deposition. These consistent metabolic alterations are associated with normoxic stabilization of hypoxia-inducible factors (HIFs) secondary to von Hippel-Lindau (VHL) mutations that occur in over 90% of ccRCC tumours. However, kidney-specific VHL deletion in mice fails to elicit ccRCC-specific metabolic phenotypes and tumour formation, suggesting that additional mechanisms are essential. Recent large-scale sequencing analyses revealed the loss of several chromatin remodelling enzymes in a subset of ccRCC (these included polybromo-1, SET domain containing 2 and BRCA1-associated protein-1, among others), indicating that epigenetic perturbations are probably important contributors to the natural history of this disease. Here we used an integrative approach comprising pan-metabolomic profiling and metabolic gene set analysis and determined that the gluconeogenic enzyme fructose-1,6-bisphosphatase 1 (FBP1) is uniformly depleted in over six hundred ccRCC tumours examined. Notably, the human FBP1 locus resides on chromosome 9q22, the loss of which is associated with poor prognosis for ccRCC patients. Our data further indicate that FBP1 inhibits ccRCC progression through two distinct mechanisms. First, FBP1 antagonizes glycolytic flux in renal tubular epithelial cells, the presumptive ccRCC cell of origin, thereby inhibiting a potential Warburg effect. Second, in pVHL (the protein encoded by the VHL gene)-deficient ccRCC cells, FBP1 restrains cell proliferation, glycolysis and the pentose phosphate pathway in a catalytic-activity-independent manner, by inhibiting nuclear HIF function via direct interaction with the HIF inhibitory domain. This unique dual function of the FBP1 protein explains its ubiquitous loss in ccRCC, distinguishing FBP1 from previously identified tumour suppressors that are not consistently mutated in all tumours.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Hypoxia can provide energy to tumor cells by activating transcriptional programs that induce glucose uptake and glycolysis.”
From Hypoxia signaling in cancer: Implications for therapeutic interventions (2023) · cites this paper as [47]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009) · Science · doi:10.1126/science.1160809 · Cited by 16,197
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113205 · Cited by 7,774
Comprehensive molecular characterization of clear cell renal cell carcinoma
The Cancer Genome Atlas Research Network (2013) · Nature · doi:10.1038/nature12222 · Cited by 3,485
Hypoxia-inducible factors and the response to hypoxic stress
Majmundar, A. J., Wong, W. J., & Simon, M. C. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.09.022 · Cited by 2,380
Self-citationReductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia
Metallo, C. M., Gameiro, P. A., Bell, E. L., Mattaini, K. R., Yang, J., Hiller, K., Jewell, C. M., Johnson, Z. R., Irvine, D. J., Guarente, L., et al. (2012) · Nature · doi:10.1038/nature10602 · Cited by 1,791
HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression
Keith, B., Johnson, R. S., & Simon, M. C. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3183 · Cited by 1,693
Self-citationFunctional genomics reveal that the serine synthesis pathway is essential in breast cancer
Possemato, R., Marks, K. M., Shaul, Y. D., Pacold, M. E., Kim, D., Birsoy, K., Sethumadhavan, S., Woo, H.-K., Jang, H. G., Jha, A. K., et al. (2011) · Nature · doi:10.1038/nature10350 · Cited by 1,683
Rini, B. I., Campbell, S. C., & Escudier, B. J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60229-4 · Cited by 1,634
Cohen, H. T., & McGovern, F. J. (2005) · New England Journal of Medicine · doi:10.1056/nejmra043172 · Cited by 1,591
Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma
Varela, I., Tarpey, P. S., Raine, K. M., Huang, D., Ong, C. K., Stephens, P., Davies, H. R., Jones, D., Lin, M., Teague, J. W., et al. (2011) · Nature · doi:10.1038/nature09639 · Cited by 1,302
Cited by
Sorted by citations
Items 301–400 of 550
Prolonged hypoxia decreases nuclear pyruvate dehydrogenase complex and regulates the gene expression
Eguchi, K., & Nakayama, K. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.09.109 · Cited by 20
Wang, Z., Chen, X., Fan, S., Zhu, C., Deng, H., Tang, J., Sun, X., Jia, S., Liao, Q., Xiao, W., et al. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.102633 · Cited by 19
Zhao, L., Quan, Y.-L., Wang, J., Wang, F., Zheng, Y., & Zhou, A. (2015) · PubMed · Cited by 19
Meta-Analysis of Tumor Stem-Like Breast Cancer Cells Using Gene Set and Network Analysis
Lee, W. J., Kim, S. C., Yoon, J.-H., Yoon, S. J., Lim, J., Kim, Y. S., Kwon, S. W., & Park, J. H. (2016) · PLoS ONE · doi:10.1371/journal.pone.0148818 · Cited by 19
Down Expression of FBP1 Is a Negative Prognostic Factor for Non–Small-Cell Lung Cancer
Sheng, H., Ying, L., Zheng, L., Zhang, D., Zhu, C., Wu, J., Feng, J., & Su, D. (2015) · Cancer Investigation · doi:10.3109/07357907.2015.1020385 · Cited by 19
Dimeric and tetrameric forms of muscle fructose-1,6-bisphosphatase play different roles in the cell
Wiśniewski, J., Piróg, M., Hołubowicz, R., Dobryszycki, P., McCubrey, J. A., Rakus, D., & Gizak, A. (2017) · Oncotarget · doi:10.18632/oncotarget.23271 · Cited by 19
Gorce, M., Lebigot, É., Arion, A., Brassier, A., Cano, A., de Lonlay, P., Feillet, F., Gay, C., Labarthe, F., Nassogne, M., et al. (2021) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12452 · Cited by 18
FBP1 is suppressed in kidney tumours
Alderton, G. K. (2014) · Nature reviews. Cancer · doi:10.1038/nrc3810 · Cited by 18
Personalized Prediction of Proliferation Rates and Metabolic Liabilities in Cancer Biopsies
Diener, C., & Reséndis-Antonio, O. (2016) · Frontiers in Physiology · doi:10.3389/fphys.2016.00644 · Cited by 18
Wang, J., Yuan, L., Liu, X., Wang, G., Zhu, Y., Qian, K., Xiao, Y., & Wang, X. (2018) · Oncology Letters · doi:10.3892/ol.2018.8473 · Cited by 18
Fructose 1,6-Bisphosphatase 1 Expression Reduces 18F-FDG Uptake in Clear Cell Renal Cell Carcinoma
Chen, R., Zhou, X., Huang, G., & Liu, J. (2019) · Contrast Media & Molecular Imaging · doi:10.1155/2019/9463926 · Cited by 18
An eleven metabolic gene signature-based prognostic model for clear cell renal cell carcinoma
Wu, Y., Wei, X., Feng, H., Hu, B., Liu, B., Luan, Y., Ruan, Y., Liu, X., Liu, Z., Wang, S., et al. (2020) · Aging · doi:10.18632/aging.104088 · Cited by 18
The functional role of Pescadillo ribosomal biogenesis factor 1 in cancer
Li, Y., Zhang, C., Pei, J., Zhang, W., Zhang, C., & Dai, D. (2021) · Journal of Cancer · doi:10.7150/jca.58982 · Cited by 18
Droppelmann, C. A., Sáez, D. E., Asenjo, J. L., Yáñez, A. J., Garcı́a-Rocha, M., Concha, I. I., Grez, M., Guinovart, J. J., & Slebe, J. C. (2015) · Biochemical Journal · doi:10.1042/bj20150269 · Cited by 19
miR-517a promotes Warburg effect in HCC by directly targeting FBP1
Zhang, D., Zhu, L., Li, T., Luo, D., Feng, X., Liu, Y., & Huang, J. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s172084 · Cited by 18
Moonlighting Enzymes at the Interface Between Metabolism and Epigenetics
van der Knaap, J. A., & Verrijzer, C. P. (2025) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-030122-044718 · Cited by 17
Proteins moonlighting in tumor metabolism and epigenetics
Lv, L., & Lei, Q. (2021) · Frontiers of Medicine · doi:10.1007/s11684-020-0818-1 · Cited by 18
GBE1 Promotes Glioma Progression by Enhancing Aerobic Glycolysis through Inhibition of FBP1
Chen, Z., Bao, H., Long, J., Zhao, P., Hu, X., Wang, H., Zhang, Y., Yang, J., Zhuge, Q., & Xia, L. (2023) · Cancers · doi:10.3390/cancers15051594 · Cited by 17
Immunometabolism: a new dimension in immunotherapy resistance
Xiao, C., Xiong, W., Xu, Y., Zou, J. P., Zeng, Y., Liu, J., Peng, Y., Hu, C., & Wu, F. (2023) · Frontiers of Medicine · doi:10.1007/s11684-023-1012-z · Cited by 18
Lin, J., Liu, Z., Chen, D., Huang, R., Cao, F., Yu, K., Li, T., Mo, H., Sheng, H., Liang, Z.-B., et al. (2025) · Nature Communications · doi:10.1038/s41467-024-55568-1 · Cited by 20
FBP1 binds to the bromodomain of BRD4 to inhibit pancreatic cancer progression.
Yang, C., Zhu, S., Yang, H., Fan, P., Meng, Z., Zhao, J., Zhang, K., & Jin, X. (2020) · PubMed Central · Cited by 17
FBP1 /miR-24-1/enhancer axis activation blocks renal cell carcinoma progression via Warburg effect
Ju, D., Liang, Y. J., Hou, G., Zheng, W., Zhang, G., Dun, X., Wei, D., Yan, F., Zhang, L., Lai, D., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.928373 · Cited by 16
Zhang, B., Li, D., Jin, X., & Zhang, K. (2020) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2020.105859 · Cited by 16
Li, Z., Du, G., Zhao, R., Yang, W., Li, C., Huang, J., Wen, Z., Li, H., & Zhang, B. (2021) · Medicine · doi:10.1097/md.0000000000027374 · Cited by 17
Neurons undergo pathogenic metabolic reprogramming in models of familial ALS
Riechers, S., Mojsilovic‐Petrovic, J., Belton, T. B., Chakrabarty, R. P., Garjani, M., Medvedeva, V., Dalton, C., Wong, Y. C., Chandel, N. S., Dienel, G. A., et al. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101468 · Cited by 16
Li, Y., Fu, Y., Zhang, Y., Duan, B., Zhao, Y., Shang, M., Cheng, Y., Zhang, K., Yu, Q., & Wang, T. (2023) · Advanced Science · doi:10.1002/advs.202203528 · Cited by 15
Wang, S., Wang, K., Yue, D., Yang, X., Pan, X., Kong, F., Zhao, R., Bie, Q., Tian, D., Zhu, S., et al. (2024) · British Journal of Cancer · doi:10.1038/s41416-024-02747-y · Cited by 15
Todisco, S., Iacobazzi, D., Santarsiero, A., Convertini, P., & Infantino, V. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102233 · Cited by 15
Epigenetic and genetic dispositions of ovarian carcinomas
Yamaguchi, K. D., Matsumura, N., Mandai, M., Baba, T., Konishi, I., & Murphy, S. K. (2014) · Oncoscience · doi:10.18632/oncoscience.82 · Cited by 15
Redox Metabolism‐Associated Molecular Classification of Clear Cell Renal Cell Carcinoma
Wei, X., Deng, W., Dong, Z., Luo, Y., Hu, X., Zhang, J., Xie, Z., Zheng, T., Tan, Y., Tang, Z., et al. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/5831247 · Cited by 15
Izumi, S., Otsuru, S., Adachi, N., Akabudike, N. M., & Enomoto‐Iwamoto, M. (2019) · PLoS ONE · doi:10.1371/journal.pone.0213912 · Cited by 15
Yang, J., Miao, D., Li, X., Zhao, C., Tan, D., Wu, S., Lu, F., Shi, J., Lv, Q., Ruan, H., et al. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1664292 · Cited by 15
Potential therapies targeting nuclear metabolic regulation in cancer
Chen, Y., Xu, J., Liu, X., Guo, L., Yi, P., & Cheng, C. (2023) · MedComm · doi:10.1002/mco2.421 · Cited by 14
The role of fructose-1,6-bisphosphatase 1 on regulating the cancer progression and drug resistance
Wang, M., Huang, X., Zhang, D., Liu, Y., & Liu, P. (2025) · Discover Oncology · doi:10.1007/s12672-025-02112-2 · Cited by 14
Palicelli, A., Croci, S., Bisagni, A., Zanetti, E., de Biase, D., Melli, B., Sanguedolce, F., Ragazzi, M., Zanelli, M., Chaux, A., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212297 · Cited by 14
PEPCK in cancer cell starvation
Leithner, K. (2015) · Oncoscience · doi:10.18632/oncoscience.252 · Cited by 14
Guo, B., Huang, X., & Broxmeyer, H. E. (2018) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000429 · Cited by 14
Epigenetic Marks Repressing Gluconeogenesis in Liver and Kidney Cancer
Leithner, K. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-3953 · Cited by 14
FBP1 expression is associated with basal-like breast carcinoma
Shi, L., Zhao, C., Pu, H., & Zhang, Q. (2017) · Oncology Letters · doi:10.3892/ol.2017.5860 · Cited by 14
Oxygen in Metabolic Dysfunction and Its Therapeutic Relevance
López-Pascual, A., Trayhurn, P., Martínez, J. A., & González‐Muniesa, P. (2021) · Antioxidants and Redox Signaling · doi:10.1089/ars.2019.7901 · Cited by 14
Zhang, S., Wang, Y., Luo, D., Cheng, Z., Zeng, Q., Wang, G., Chen, M., Zhang, S., & Luo, P. (2023) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.18059 · Cited by 13
Mizuno, H., Koya, J., Masamoto, Y., Kagoya, Y., & Kurokawa, M. (2021) · Cancer Science · doi:10.1111/cas.15098 · Cited by 13
Gajewska, J., Chełchowska, M., Rychłowska-Pruszyńska, M., Klepacka, T., & Ambroszkiewicz, J. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11061663 · Cited by 13
Li, H., Li, M., Pang, Y., Liu, F., Sheng, D., & Cheng, X. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2017.7665 · Cited by 13
Ren, X. S., Liu, G., & Zhou, J. (2025) · Cancer Cell International · doi:10.1186/s12935-025-03760-8 · Cited by 12
Ghanem, A., Kitanovic, A., Holzwarth, J., & Wölfl, S. (2017) · Microbial Cell · doi:10.15698/mic2017.02.557 · Cited by 12
Cheung, R. A., Kraft, A. M., & Petty, H. R. (2021) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00176.2021 · Cited by 12
Huang, S., Luo, Q., Huang, J., Wei, J., Wang, S., Hong, C., Qiu, P., & Li, C. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.902064 · Cited by 12
Xu, Y., Tran, L. H., Tang, J., Nguyen, V. Q., Sewell, E., Xiao, J., Hino, C., Wasnik, S., Francis-Boyle, O. L., Zhang, K. K., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911387 · Cited by 12
Annels, N. E., Denyer, M., Nicol, D. L., Hazell, S., Silvanto, A., Crockett, M. G., Hussain, M., Möller‐Levet, C. S., & Pandha, H. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03558-5 · Cited by 12
Jeong, G., Kang, D., Kim, A., Han, K. H., Jeon, H. R., & Kim, D. (2019) · Scientific Reports · doi:10.1038/s41598-019-42669-x · Cited by 12
Wang, B., Yuan, Y., Zou, Y., Qi, Z., Huang, G., Liu, Y., Xia, S., Huang, Y., & Huang, Z. (2021) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000001185 · Cited by 12
An RNA interference screen identifies new avenues for nephroprotection
Zynda, E. R., Schott, B., Gruener, S., Wernher, E., Duchâteau-Nguyen, G., Ebeling, M., & Kandel, E. (2015) · Cell Death and Differentiation · doi:10.1038/cdd.2015.128 · Cited by 12
Zhang, Q., Ding, L., Zhou, T.-R., Zhai, Q., Ni, C., Liang, C., & Li, J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.982426 · Cited by 12
Phillips, R. (2014) · Nature Reviews Urology · doi:10.1038/nrurol.2014.200 · Cited by 12
Molecular Biology of Kidney Cancer
Kaelin, W. G. (2015) · Springer eBooks · doi:10.1007/978-3-319-17903-2_3 · Cited by 12
Erratum: An RNA interference screen identifies new avenues for nephroprotection
Zynda, E. R., Schott, B., Gruener, S., Wernher, E., Duchâteau-Nguyen, G., Ebeling, M., & Kandel, E. (2016) · Cell Death and Differentiation · doi:10.1038/cdd.2016.98 · Cited by 12
The big picture: exploring the metabolic cross-talk in cancer
Schulze, A., & Yuneva, M. O. (2018) · Disease Models & Mechanisms · doi:10.1242/dmm.036673 · Cited by 12
Shi, J., Miao, D., Lv, Q., Tan, D., Xiong, Z., & Zhang, X. (2023) · Biomedicines · doi:10.3390/biomedicines11092499 · Cited by 12
The gluconeogenesis enzyme PCK2 has a non-enzymatic role in proteostasis in endothelial cells
de Zeeuw, P., Treps, L., García‐Caballero, M., Harjes, U., Kalucka, J. M., Legher, C. D., Brepoels, K., Peeters, K., Vinckier, S., Souffreau, J., et al. (2024) · Communications Biology · doi:10.1038/s42003-024-06186-6 · Cited by 11
Peng, X., Ma, L., Chen, X., Tang, F., & Zong, X. (2024) · Oncology Reports · doi:10.3892/or.2024.8769 · Cited by 11
Li, C., Zhu, L., Yang, Y., Zhang, T., Chen, C., Zhang, Y., Ji, W., Duan, X., Xue, W., Li, L., et al. (2024) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2024.167559 · Cited by 11
Activated ATF6α is a hepatic tumour driver restricting immunosurveillance
Li, X., Lebeaupin, C., Kadianaki, A., Druelle-Cedano, C., Vesper, N., Rennert, C., Huguet‐Pradell, J., Ramos, B. G., Fan, C., Piecyk, R. S., et al. (2026) · Nature · doi:10.1038/s41586-025-10036-8 · Cited by 11
Self-citationChoudhury, F. K., Hackman, G. L., Lodi, A., & Tiziani, S. (2020) · Cancers · doi:10.3390/cancers12082147 · Cited by 12
Crosstalk of Epigenetic and Metabolic Signaling Underpinning Glioblastoma Pathogenesis
Markouli, M., Strepkos, D., Papavassiliou, K. A., Papavassiliou, A. G., & Piperi, C. (2022) · Cancers · doi:10.3390/cancers14112655 · Cited by 12
Hepatic but not Intestinal FBP1 Is Required for Fructose Metabolism and Tolerance
Bai, Q., Liu, Y., Wang, C.-M., Wang, J.-R., Feng, Y., Ma, X., Yang, X., Shi, Y., & Zhang, W. J. (2023) · Endocrinology · doi:10.1210/endocr/bqad054 · Cited by 12
Guo, T., Jiang, L., Wang, T., Zhang, J., Liu, Y., Wang, X., Zhang, N., Chen, S., & Wang, X. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e16479 · Cited by 11
Aljaylani, A., Fluitt, M. B., Piselli, A., Shepard, B. D., Tiwari, S., & ECELBARGER, C. A. (2020) · Cellular Physiology and Biochemistry · doi:10.33594/000000248 · Cited by 11
Wang, L., Wang, J., Shen, Y., Zheng, Z., & Sun, J. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/6766787 · Cited by 11
Lin, E., Zhu, P., Ye, C., Huang, M., Liu, X., Tian, K., Tang, Y., Zeng, J., Cheng, S., Liu, J., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.830220 · Cited by 10
George, M. P., Gladwin, M. T., & Graham, B. B. (2020) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2020-0099tr · Cited by 10
Cassago, C. A. D. G., Dias, M. M., Pinheiro, M. P., Pasquali, C. C., Bastos, A. C. S., Islam, Z., Consonni, S. R., de Oliveira, J. F., Gomes, E. R. M., Ascenção, C. F. R., et al. (2018) · Biochemistry · doi:10.1021/acs.biochem.8b00773 · Cited by 10
Kundu, A., Brinkley, G. J., Nam, H., Karki, S., Kirkman, R. L., Pandit, M., Shim, E., Widden, H., Liu, J., Heidarian, Y., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci171294 · Cited by 9
Song, Q., Sui, J., Yang, Y., Zhang, H., Li, Y., & Yang, L. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.139273 · Cited by 9
Pt(IV) Complexes as Anticancer Drugs and Their Relationship with Oxidative Stress
Iova, V., Ţincu, R. C., Scrobotă, I., & Tudosie, M. S. (2025) · Biomedicines · doi:10.3390/biomedicines13040981 · Cited by 10
Obeidat, N. A., Zihlif, M., Alqudah, D. A., Alshaer, W., Alqaraleh, M., & Abdalla, S. (2022) · Biomedical Reports · doi:10.3892/br.2022.1564 · Cited by 9
Zhu, W., Zhu, Y., Zhang, S., Zhang, W., Si, Z., Bai, Y., Fu, Y., Fu, Y., Zhang, Y., Zhang, L., et al. (2023) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2023.106251 · Cited by 9
Brauer, N., Maruta, Y., Lisci, M., Strege, K., Oschlies, I., Nakamura, H., Böhm, S., Lehmberg, K., Brandhoff, L., Ehl, S. R., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1151166 · Cited by 9
Torabidastgerdooei, S., Roy, M.-È., & Annabi, B. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1265698 · Cited by 9
Zhang, Q., Wang, T., Wang, D., Liu, J.-X., Yu, W., Liu, X., Xiang, X., Dong, K., You, F., Zhang, G., et al. (2015) · Cancer Genetics · doi:10.1016/j.cancergen.2015.09.006 · Cited by 9
Wang, Z., He, T., Lv, W., & Hu, J. (2023) · Translational Cancer Research · doi:10.21037/tcr-22-2200 · Cited by 9
Targeting Metabolic Pathways in Kidney Cancer
Hoerner, C. R., Miao, S. Y., Hsieh, J. J.-D., & Fan, A. C. (2020) · The Cancer Journal · doi:10.1097/ppo.0000000000000472 · Cited by 9
Winter is coming: Regulation of cellular metabolism by enzyme polymerization in dormancy and disease
Montrose, K., Cabezas, R. M. L., Paukštytė, J., & Saarikangas, J. (2020) · Experimental Cell Research · doi:10.1016/j.yexcr.2020.112383 · Cited by 9
Metabolic reprogramming and elevation of glutathione in chromophobe renal cell carcinomasPreprint
Xiao, Y., Clima, R., Busch, J. F., Rabien, A., Kilic, E., Villegas, S. L., Türkmen, S., Timmermann, B., Attimonelli, M., Jung, K., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/649046 · Cited by 9
Kurlekar, S., Lima, J. D. C. C., Li, R., Lombardi, O., Masson, N., Barros, A. B., Pontecorvi, V., Mole, D. R., Pugh, C. W., Adam, J., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-3248 · Cited by 8
Mitochondrial VHL rewires cell metabolism in hypoxia
Li, G., Pan, W., Wu, L., Cai, Z., Chen, H., Wu, X., Yu, T., Liao, K., Zhang, H., 温星桥, et al. (2025) · Cell Metabolism · doi:10.1016/j.cmet.2025.11.013 · Cited by 10
Self-citationBan, F., Hu, L., Zhou, X., Zhao, Y., Mo, H., Li, H., & Zhou, W. (2021) · Food Science & Nutrition · doi:10.1002/fsn3.2392 · Cited by 8
Yu, H., Raza, S. H. A., Pan, Y., Cheng, G., Mei, C., & Zan, L. (2023) · Animals · doi:10.3390/ani13061060 · Cited by 8
Ren, D., Li, W., Zeng, R., Liu, X., Liang, H., Xiong, W., Yang, C., & Jin, X. (2024) · Cell Death and Differentiation · doi:10.1038/s41418-024-01282-w · Cited by 8
Fructose 1,6-bisphosphatase as a promising target of anticancer treatment
Gizak, A., Budziak, B., Domaradzka, A., Pietras, Ł., & Rakus, D. (2024) · Advances in Biological Regulation · doi:10.1016/j.jbior.2024.101057 · Cited by 8
The effect of trans-resveratrol on the expression of the human DNA-repair associated genes
Uchiumi, F., Arakawa, J., Takihara, Y., Akui, M., Ishibashi, S., & Tanuma, S. (2016) · Integrative Molecular Medicine · doi:10.15761/imm.1000246 · Cited by 9
Godfrey, J. T., Riscal, R., Skuli, N., & Simon, M. C. (2022) · Cancer & Metabolism · doi:10.1186/s40170-022-00280-1 · Cited by 9
Self-citationAgudelo, J. P., Upadhyay, D., Zhang, D., Zhao, H., Nolley, R., Sun, J., Agarwal, S., Bok, R., Vigneron, D. B., Brooks, J. D., et al. (2022) · Metabolites · doi:10.3390/metabo12111117 · Cited by 8
Lv, X., Zhang, K.-B., Guo, X., Pei, L., & Feng, L. (2022) · Medicine · doi:10.1097/md.0000000000030658 · Cited by 8
Chen, Y., Jiang, S., Lu, Z., Xue, D., Xia, L., Lu, J., Wang, H., Xu, L., Li, L., & Li, G. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14748 · Cited by 8
Liu, H., Wu, Q., Liu, W., Liu, Y.-D., Fu, Q., Zhang, W., Xu, L., & Xu, J. (2015) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2014.15.23.10217 · Cited by 8
Lichner, Z., Mac‐Way, F., & Yousef, G. M. (2017) · European Urology Focus · doi:10.1016/j.euf.2017.08.003 · Cited by 8
Integrated analysis of MIOX gene in prognosis of clear-cell renal cell carcinoma
Wang, Y., Lu, J., Lin, B.-H., Chen, J., Lin, F., Zheng, Q., Xue, X., Wei, Y., Chen, S., & Xu, N. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07698-7 · Cited by 8
Yang, Y., Ma, Y., Fan, S., Zhu, J., Ye, B., Zhang, R., Li, J., Li, H., Zheng, Z., Li, Y., et al. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02426-8 · Cited by 7
New Method Enhanced Extraction of Protein Signatures of Renal Cell Carcinoma from Proteomics Data
Liu, H., Ma, Z., Lih, T. M., Chen, L., Hu, Y., Wang, Y., Sun, Z., Huang, Y., Xu, Y., & Zhang, H. (2025) · Journal of Proteome Research · doi:10.1021/acs.jproteome.5c00414 · Cited by 7
Metadata
- Authors
- Li, B., Qiu, B., Lee, D. S. M., Walton, Z. E., Ochocki, J. D., Mathew, L. K., Mancuso, A., Gade, T. P. F., Keith, B., Nissim, I., & Simon, M. C.
- Affiliations
- Abramson Cancer Center (US)
- Howard Hughes Medical Institute (US)
- University of Pennsylvania (US)
- Children's Hospital of Philadelphia (US)
- Corresponding author
- Simon, M. Celeste
- ORCID
- Venue
- Nature
- Published
- 2014-07-20
- Volume
- 513
- Issue
- 7517
- Pages
- 251-255
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4162811
- OpenAlex
- W2069663698
- Cited by
- 535
- References
- 31
- Citations by year
- 2026: 24 · 2025: 38 · 2024: 44 · 2023: 44 · 2022: 48 · 2021: 64 · 2020: 54 · 2019: 42 · 2018: 54 · 2017: 42 · 2016: 40 · 2015: 33 · 2014: 6
- FWCI
- 12.92
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- National Institutes of Health
- National Cancer Institute (F30CA177106, P01CA104838, CA104838, F32CA192758, P30CA016520)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK053761, DK-053761, R56DK053761)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Keywords
- FBP1, clear cell renal cell carcinoma, von Hippel-Lindau protein, hypoxia-inducible factor, glycolysis, pentose phosphate pathway, Warburg effect, renal tubular epithelial cells, tumor progression, chromatin remodeling, cancer metabolism, epigenetic regulation, gluconeogenesis
- MeSH terms
- Animals, Carcinoma, Renal Cell, Cell Line, Epithelial Cells, Glycolysis, Fructose-Bisphosphatase, Humans, Kidney Neoplasms, Models, Molecular, NADP, Swine, Protein Structure, Tertiary, Disease Progression, Cell Line, Tumor, Cell Proliferation, Basic Helix-Loop-Helix Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
